First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+metastatic breast cancer (MBC).

被引：36
|
作者：
Alsina, Maria
Boni, Valentina
Schellens, Jan H. M.
Moreno, Victor
Bol, Kees
Westendorp, Martine
Sirulnik, L. Andres
Tabernero, Josep
Calvo, Emiliano
机构：
[1] Vall Hebron Univ Hosp, Barcelona, Spain
[2] START Madrid CIOCC, Hosp HM Univ Sanchinarro, Madrid, Spain
[3] Netherlands Canc Inst, Amsterdam, Netherlands
[4] Start Madrid FJD, Hosp Fdn, Madrid, Spain
[5] Merus NV, Utrecht, Netherlands
[6] Vall Hebron Univ Hosp, Inst Oncol VHIO, Barcelona, Spain
[7] START Madrid, Centro Integral Oncol Clara Campal, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.2522
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2522
引用
收藏
页数：6
相关论文
共 50 条
  • [1] A Phase I/Il Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3 in Patients with Solid Tumors
    Calvo, Emiliano
    Alsina, Maria
    Schellens, Jan H. M.
    Huitema, Alwin D. R.
    Tabernero, Josep
    de Vries-Schultink, Aurelia
    Boni, Valentina
    Doger, Bernard
    Geuijen, Cecile
    Doornbos, Robert
    Bol, Kees
    Westendorp, Martine
    Throsby, Mark
    Bakker, Lex
    Shamsili, Setareh
    CANCER RESEARCH, 2016, 76
  • [2] Preclinical activity of MCLA-128, an ADCC enhanced bispecific IgG1 antibody targeting the HER2: HER3 heterodimer
    Geuijen, Cecile
    Rovers, Eric
    Nijhuis, Roy
    den Blanken-Smit, Renate
    Visser, Therese
    Bartelink, Willem
    Kramer, Arjen
    Zondag-van der Zande, Vanessa
    Clements, Carina
    Kaldenberg, Linda
    Nieuwenhuizen, Nellie
    van Loo, Pieter Fokko
    Roovers, Rob
    Gallenne, Tristan
    Price, Leo
    Shamsili, Setareh Van Driel
    Bakker, Lex
    Logtenberg, Ton
    de Kruif, John
    Throsby, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Mechanism of action of MCLA-128, a humanized bispecific IgG1 antibody targeting the HER2: HER3 heterodimer
    Geuijen, Cecile
    Rovers, Eric
    Gallenne, Tristan
    Maussang-Detaille, David
    Kramer, Arjen
    Nieuwenhuizen, Nellie
    Clements, Carina
    van Zoest, Katinka
    Nijhuis, Roy
    Visser, Therese
    Den Blanken-Smit, Renate
    Bartelink, Willem
    Zondag-van der Zande, Vanessa
    Kaldenberg, Linda
    van Loo, Pieter-Fokko
    Roovers, Rob
    Doornbos, Robert
    Price, Leo
    Braam, Stefan
    van Driel, Setareh
    Bakker, Lex
    Logtenberg, Ton
    de Kruif, John
    Throsby, Mark
    CANCER RESEARCH, 2015, 75
  • [4] Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+metastatic gastric/gastroesophageal junction cancer (GC/GEJ)
    Alsina, M.
    Varga, A.
    Amatu, A.
    Schellens, J. H. M.
    Witteveen, P. O.
    Boni, V.
    Moreno, V.
    Bol, K.
    Lourbakos, A.
    Ferrer, M. Magin
    Wasserman, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Phase 2 Study of Zenocutuzumab (MCLA-128), a Bispecific HER2/HER3 Antibody in NRG1 Fusion-Positive Advanced Solid Tumors
    Schram, A.
    Macarulla, T.
    O'Reilly, E.
    Rodon, J.
    Wolpin, B.
    Ou, S.
    Kim, D.
    Yang, J. C.
    Lam, J.
    De Langen, A.
    Boni, V.
    Cerea, G.
    Duruisseaux, M.
    Felip, E.
    Liu, S.
    O'Kane, G.
    Senecal, F.
    Nagasaka, M.
    Starr, J.
    Wasserman, E.
    Drilon, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S675 - S675
  • [6] Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors
    Aurelia H. M. de Vries Schultink
    Kees Bol
    Robert P. Doornbos
    Anastasia Murat
    Ernesto Wasserman
    Thomas P. C. Dorlo
    Jan H. M. Schellens
    Jos H. Beijnen
    Alwin D. R. Huitema
    Clinical Pharmacokinetics, 2020, 59 : 875 - 884
  • [7] Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors
    Schultink, Aurelia H. M. de Vries
    Bol, Kees
    Doornbos, Robert P.
    Murat, Anastasia
    Wasserman, Ernesto
    Dorlo, Thomas P. C.
    Schellens, Jan H. M.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    CLINICAL PHARMACOKINETICS, 2020, 59 (07) : 875 - 884
  • [8] Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
    Aurelia H. M. de Vries Schultink
    Robert P. Doornbos
    Alexander B. H. Bakker
    Kees Bol
    Mark Throsby
    Cecile Geuijen
    David Maussang
    Jan H. M. Schellens
    Jos H. Beijnen
    Alwin D. R. Huitema
    Investigational New Drugs, 2018, 36 : 1006 - 1015
  • [9] Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose
    Schultink, Aurelia H. M. de Vries
    Doornbos, Robert P.
    Bakker, Alexander B. H.
    Bol, Kees
    Throsby, Mark
    Geuijen, Cecile
    Maussang, David
    Schellens, Jan H. M.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1006 - 1015
  • [10] A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (MBC): Final results
    Vogel, C. L.
    Burris, H. A.
    Limentani, S.
    Borson, R.
    O'Shaughnessy, J.
    Vukelja, S.
    Agresta, S.
    Klencke, B.
    Birkner, M.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345